Acurx to Present at Alliance Global Partners Showcase Amidst CDI Trial Launch
Event summary
- Acurx Pharmaceuticals CEO David Luci will participate in a virtual fireside chat at Alliance Global Partners’ Healthcare Company Showcase on May 24, 2025.
- The presentation will be replayed on Acurx’s website following the event.
- Acurx is developing a new class of antibiotics targeting Gram-positive bacteria, including *Clostridioides difficile*.
- The company recently launched a clinical trial for ibezapolstat in patients with multiply-recurrent CDI (rCDI), aiming to shift treatment paradigms.
- Ibezapolstat, Acurx’s lead candidate, is Phase 3 ready and seeks FDA approval via the Limited Population Pathway.
The big picture
Acurx's focus on antibiotics targeting resistant Gram-positive bacteria addresses a critical and growing public health need, particularly with the rise of *C. difficile* infections. The company's strategy of pursuing the Limited Population Pathway represents an attempt to accelerate approval for a niche indication, but also carries inherent risks related to market size and reimbursement. The fireside chat provides an opportunity to gauge investor sentiment and assess the company’s progress in securing funding and executing its clinical development plan.
What we're watching
- Clinical Execution
- The success of the open-label pilot trial in rCDI patients will be critical in informing the design and potential success of the subsequent Phase 3 registration trial, and any setbacks could delay approval timelines.
- Financing Needs
- Advancing ibezapolstat to international Phase 3 trials hinges on securing additional financing, and the company's ability to do so will dictate the pace of its development program.
- Regulatory Pathway
- Acurx’s plan to leverage the FDA’s Limited Population Pathway for approval will be closely scrutinized, as the pathway’s requirements and potential limitations could impact the approval process and commercial viability of ibezapolstat.
Related topics